What is the clinical value of genomic profiling in rare cancers?
Early studies investigated the potential of genomic profiling, but prospective and comprehensive data are required to support wider implementation
Epigenetic information could harbour biomarkers of diagnosis and prognosis
Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment
Tailored use of chemotherapy may benefit some early-stage ER+/HER2– breast cancers
Results from two studies suggest that withholding chemotherapy for some patients may not impact efficacy, but an understanding of clinical and biological features is paramount
Study findings refine the use of ctDNA to track resistance to endocrine therapy in advanced breast cancer
A timing window for testing ESR1 mutations in the blood was identified
An ESMO roadmap for implementing molecular tumour boards
Newly released recommendations address key areas to facilitate the integration of precision oncology in clinical practice
Is it time for pathologists to take a more active role in lung cancer?
According to Heine H. Hansen Award winner, Prof. Keith Kerr, pathologists can help translate scientific understanding into clinical practice
New data show promise in using liquid biopsies to tailor immunotherapy
Studies explore the prognostic and predictive values of circulating DNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear cells
Education sets the basis for an AI-driven future of oncology
The deployment of artificial intelligence could lead to substantial advances in cancer care, but collaborative efforts are needed to increase trust among end users
Translating cancer genome insights into practical clinical tools
Findings from complex statistical modelling can form the basis for easy-to-use precision diagnostic and risk-stratification tools to help inform management decisions
Studies present a wider application of sequencing techniques for the treatment of cancer
Whole-genome sequencing and single-cell sequencing can provide valuable insights not only in the identification of new therapy targets, but also to assess minimal residual disease and overcome treatment resistance